New hope against superbug: antibiotic combo targets resistant klebsiella
NCT ID NCT07369518
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test the antibiotic combination ceftazidime-avibactam on 100 patients with healthcare-associated infections caused by carbapenem-resistant Klebsiella pneumoniae. Researchers will collect samples from blood, urine, and other sites to identify the bacteria and check for resistance genes. The goal is to see how well the drug works and understand the genetic makeup of these superbugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Ceftazidime-avibactam
- What this could lead to
- If successful, this could help doctors choose better antibiotics for hard-to-treat Klebsiella infections, potentially improving patient outcomes.
- What could go wrong
- This is a small, early-stage study that has not yet started recruiting. It focuses on lab testing and may not directly lead to new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBIOTIC SENSITIVITY TESTING OF DIFFERENT ANTIBIOTICS ACCORDING TO CLSI 25 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of medicine Sohag University
Sohag, Egypt